- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06815367
Pneumatisk kompression mot blodflödesbegränsning för muskelåtervinning
Jämförelse av effekterna av pneumatisk komprimering och blodflödesbegränsningsterapi på muskelåtervinning
Both BFR and intermittent pneumatic compression are purported to decrease symptoms associated with exercise induced muscle damage (EIMD) that cause delayed onset muscle soreness (DOMS). Blood flow restriction relies on applying pressurized cuffs to the most proximal portion of the limb. Another form of recovery often relied upon is pneumatic compression. The mechanism by which pneumatic compression works is similar to that of a massage, whereby the device progressively increases the pressure on a portion of the limb before releasing and moving further up the limb.The purpose of this study is determine whether BFR or pneumatic compression can be used to decreased DOMS which may indicate enhanced recovery.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Inte tillämpbar
Kontakter och platser
Studieorter
-
-
California
-
Los Angeles, California, Förenta staterna, 90033
- University of Southern California
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- 18-30 years of age
- Recreationally active population
- Women should be on a form of hormonal contraception.
- No current musculoskeletal injuries or pathologies
- Must answer "yes" to all PAR-Q questions.
Exclusion Criteria:
- Individuals that routinely train trail running
- Discomfort when running
- Deep vein thrombosis
- Blood clots
- Cancerous lesions
- Sensory or mental impairment
- Unstable fractures
- Acute pulmonary edema
- Acute thrombophlebitis
- Acute congestive cardiac failure
- Acute infections
- Episodes of pulmonary embolism
- Wounds, lesions, infection, or tumors
- Bone fractures or dislocations
- Increased venous and lymphatic return
- Answers "no" to any of the PAR-Q screening questions
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Inget ingripande: Control
The participants will be asked to refrain from exercise 24 hours prior to and following the exercise. Participants will complete all pre-exercise tests (DOMS, CMJ). The exercise consists of running on a treadmill situated at a -10% grade at 9 km/hr (5.59 mph) for 20 minutes. This is proceeded and followed by 5 minute warm-up/cool-down periods. Those that are allocated to the "control" group, will not receive treatment after the downhill running protocol. |
|
|
Experimentell: Pneumatic compression
The participants will be asked to refrain from exercise 24 hours prior to and following the exercise. Participants will complete all pre-exercise tests (DOMS, CMJ). The exercise consists of running on a treadmill situated at a -10% grade at 9 km/hr (5.59 mph) for 20 minutes. This is proceeded and followed by 5 minute warm-up/cool-down periods. Those allocated to the "pneumatic compression" group will receive 20 minutes of pneumatic compression at 100 mmHg. |
Following downhill running protocol, participants will complete 20 minutes of pneumatic compression at 100 mmHg. |
|
Experimentell: Blood flow restriction
The participants will be asked to refrain from exercise 24 hours prior to and following the exercise. Participants will complete all pre-exercise tests (DOMS, CMJ). The exercise consists of running on a treadmill situated at a -10% grade at 9 km/hr (5.59 mph) for 20 minutes. This is proceeded and followed by 5 minute warm-up/cool-down periods. Those allocated to the "BFR" group will receive 4 rounds of treatment: 3 minutes will be spent at 100% of resting limb occlusion pressure, followed by 2 minutes of 0% occlusion. |
Following the downhill running protocol, participants will complete 4 rounds of treatment: 3 minutes at 100% resting limb occlusion pressure, 2 minutes of 0% resting limb occlusion pressure. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Counter Movement Jump Height
Tidsram: Baseline to immediately following exercise
|
Participants will be asked to complete three consecutive counter movement jumps with hands on hips. The CMJ will be used as an indirect measure of muscle function. |
Baseline to immediately following exercise
|
|
Sedentary delayed onset muscle soreness
Tidsram: Baseline to 24-hours following exercise
|
Using a visual analog scale (0 = no soreness; 10= worst soreness imaginable), participants will be asked to rate their level of soreness while at rest. |
Baseline to 24-hours following exercise
|
|
Sedentary delayed onset muscle soreness
Tidsram: Baseline to immediately after treatment
|
Using a visual analog scale (0 = no soreness; 10= worst soreness imaginable), participants will be asked to rate their level of soreness while at rest. |
Baseline to immediately after treatment
|
|
Active delayed onset muscle soreness
Tidsram: Baseline to 24-hours following exercise
|
Using an 11-point visual analog scale (0 = no soreness; 10= worst soreness imaginable) , participants will be asked to rate their level of soreness while completing a wall sit. |
Baseline to 24-hours following exercise
|
|
Active delayed onset muscle soreness
Tidsram: Baseline to immediately after treatment
|
Using an 11-point visual analog scale (0 = no soreness; 10= worst soreness imaginable) , participants will be asked to rate their level of soreness while completing a wall sit. |
Baseline to immediately after treatment
|
|
Counter Movement Jump Height
Tidsram: Baseline to immediately following exercise, approximately 30 minutes after baseline
|
Participants will be asked to complete three consecutive counter movement jumps with hands on hips. The CMJ will be used as an indirect measure of muscle function. |
Baseline to immediately following exercise, approximately 30 minutes after baseline
|
|
Sedentary delayed onset muscle soreness
Tidsram: Baseline to immediately following exercise, approximately 30 minutes after baseline
|
Using a visual analog scale (0 = no soreness; 10= worst soreness imaginable), participants will be asked to rate their level of soreness while at rest. |
Baseline to immediately following exercise, approximately 30 minutes after baseline
|
|
Active delayed onset muscle soreness
Tidsram: Baseline to immediately following exercise, approximately 30 minutes after baseline
|
Using an 11-point visual analog scale (0 = no soreness; 10= worst soreness imaginable) , participants will be asked to rate their level of soreness while completing a wall sit. |
Baseline to immediately following exercise, approximately 30 minutes after baseline
|
|
Counter Movement Jump Height
Tidsram: Baseline to 24 hours following treatment
|
Participants will be asked to complete three consecutive counter movement jumps with hands on hips. The CMJ will be used as an indirect measure of muscle function. |
Baseline to 24 hours following treatment
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- HS-23-00594
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .